Course Videos
What is the role of NGS for identifying “HER-2 enrichment” therapy? What is the situation in Asia as far deploying NGS in patients with breast cancer?
How is hybrid-based NGS leading to improved stratification of patients with breast cancer?
How is hybrid-based NGS leading to improved stratification of patients with breast cancer?
What is your recommendation regarding the timing of use for NGS-based genomic profiling? Do you believe it should be used early in the neoadjuvant setting or only in advanced, resistant, or metastatic disease?
In what subtypes of cancer have we validated the efficacy of comprehensive NGS screening for improving outcomes by aligning molecular targets with appropriate therapies and predictive biomarkers of efficacy?
What is the role of NGS for the assessment of gastric and colorectal cancer? (Korean)
What is the role of NGS for the assessment of gastric and colorectal cancer?
How are you using NGS and comprehensive genomic profiling in South Korea, and in which cancer subtypes are you using NGS to identify actionable molecular targets and targeted treatment strategies?
Can you give us a roadmap and detailed rationale for how and when to deploy NGS in the setting of prostate cancer? How do improve the content yields of prostate biopsies? How do we ferret out tumor heterogeneity issues?
Given the heterogeneity of genomic aberrations you have described for prostate cancer, what are the limitations of so-called targeted, PCR-based “hot spot” panels for identifying actionable molecular profiles, homozygous deletions and ...
Can you review for us the implications of your study on PTEN genomic rearrangements and loss in prostate cancer and the implications for NGS-based profiling in this disease?
In what way does systematic profiling with NGS optimize genomic and molecular stratification for prostate cancer, and what actionable subgroups and aberrations have you identified based on comprehensive genomic assessment?
How is NGS, identification of microsatellite instability and mismatch repair defects, and molecular target stratification that comprehensive genomic profiling improving management of prostate cancer?